United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 9th. The shares were sold at an average price of $544.94, for a total value of $5,176,930.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $176,801,968.42. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $540.03 on Thursday. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The stock has a market cap of $23.16 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 3.89 and a beta of 0.49. The business’s fifty day moving average is $513.58 and its 200-day moving average is $540.32.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 EPS. Equities research analysts predict that United Therapeutics Corporation will post 26.40 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reached a global settlement resolving all six pending lawsuits with Liquidia. The agreement eliminates significant patent and antitrust uncertainty and should reduce future legal expenses. United Therapeutics Reaches Major Pulmonary Hypertension Settlement
• Positive Sentiment: The settlement is financially favorable in the near term because Liquidia will make payments totaling approximately $380.7 million. It also preserves United Therapeutics’ ability to compete in pulmonary arterial hypertension while bringing greater clarity to the market. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
• Positive Sentiment: Jefferies raised its price target for UTHR to $728, while the broader analyst consensus remains favorable, with an average target near $627 and most analysts rating the stock Buy or Overweight. United Therapeutics Price Target Raised to $728
• Neutral Sentiment: The latest quarterly results showed stronger-than-expected adjusted earnings, but revenue missed estimates and declined year over year. This mixed operating backdrop may be limiting enthusiasm despite the legal resolution.
• Negative Sentiment: By settling, United Therapeutics allows Liquidia’s YUTREPIA to remain available for PAH patients. That could increase competition with Tyvaso and other United Therapeutics products, although the settlement reportedly imposes limitations on YUTREPIA’s labeling and does not provide unrestricted access to every indication. What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring
• Negative Sentiment: CEO Martine Rothblatt disclosed sales of 9,500 UTHR shares, worth roughly $5.2 million. The transaction is relatively small compared with her remaining stake but may add modest sentiment pressure. United Therapeutics CEO Stock Sale

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Callan Family Office LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth $1,217,000. Andra AP fonden raised its position in shares of United Therapeutics by 33.5% during the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after purchasing an additional 8,760 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of United Therapeutics during the second quarter valued at $3,359,000. Seven Fleet Capital Management LP purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $633,000. Finally, Partners Capital Investment Group LLP purchased a new stake in shares of United Therapeutics during the second quarter valued at $1,691,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Morgan Stanley boosted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. The Goldman Sachs Group began coverage on shares of United Therapeutics in a research note on Thursday, September 24th. They issued a “sell” rating and a $321.00 price objective on the stock. Finally, Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $639.08.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.